Safety of medications used to treat acute agitation

Journal of Emergency Medicine

Volumn 27, Issue 4 SUPPL., 2004, Pages

  Currier, Glenn W ^a,b   Allen, Michael H ^c   Bunney, E Bradshaw ^d   Daniel, David G ^e   Francis, Andrew ^f   Jagoda, Andy ^g   Zimbroff, Dan ^h  

^a Department of Psychiatry ^*

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO HOSPITAL   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e Bioniche Development Inc   (United States)

^f STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h Pacific Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DOFETILIDE; DROPERIDOL; FLUOXETINE; FLUVOXAMINE; GATIFLOXACIN; HALOFANTRINE; HALOPERIDOL; KETOCONAZOLE; LORAZEPAM; MEFLOQUINE; MESORIDAZINE; MOXIFLOXACIN; OLANZAPINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PROBENECID; QUINIDINE; RIFAMPICIN; RISPERIDONE; SOTALOL; SPARFLOXACIN; THIORIDAZINE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

AGITATION; AREA UNDER THE CURVE; ATAXIA; BRADYCARDIA; CARDIOTOXICITY; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONFUSION; DEHYDRATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG GLUCURONIDATION; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; DRUG SCREENING; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; LETHARGY; LIVER TOXICITY; MIOSIS; MORTALITY; NEPHROTOXICITY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; SEDATION; SINUS BRADYCARDIA; STATISTICAL SIGNIFICANCE; SYNCOPE; TACHYCARDIA;

EID: 7044264390     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2004.09.003     Document Type: Article

References (64)

1. A. Trenton, G. Currier, F. Zwemer Fatalities associated with therapeutic use and overdose of atypical antipsychotics CNS Drugs 17 2003 307 324
2. R.T. Schillings, S.F. Sisenwine, M.H. Schwartz, H.W. Ruelius Lorazepam: glucuronide formation in the cat Drug Metab Dispos 3 1975 85 88
3. S. Kudo, T. Ishizaki Pharmacokinetics of haloperidol: an update Clin Pharmacokinet 37 1999 435 456
4. E.E. Samara, R.G. Granneman, G.F. Witt, J.H. Cavanaugh Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam J Clin Pharmacol 37 1997 442 450
5. D.R. Abernethy, D.J. Greenblatt, B. Ameer, R.I. Shader Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation J Pharmacol Exp Ther 234 1985 345 349
6. A. Klimke, E. Klieser Sudden death after intravenous application of lorazepam in a patient treated with clozapine Am J Psychiatry 151 1994 780
7. Ativan (package insert). Philadelphia, PA: Wyeth Laboratories; 2002.
8. J. Fang, G.B. Baker, P.H. Silverstone, R.T. Coutts Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol Cell Mol Neurobiol 17 1997 227 233
9. H.E. Alexander Jr, K. McCarty, M.B. Giffen Hypotension and cardiopulmonary arrest associated with concurrent haloperidol and propranolol therapy JAMA 252 1984 87 88
10. R.J. Fruncillo, W.J. Gibbons, P.H. Vlasses, R.K. Ferguson Severe hypotension associated with concurrent clonidine and antipsychotic medication Am J Psychiatry 142 1985 274
11. J. Fang, M. Bourin, G.B. Baker Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 Naunyn Schmiedebergs Arch Pharmacol 359 1999 147 151
12. E. Spina, A. Avenoso, M.G Scordo Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction J Clin Psychopharmacol 22 2002 419 423
13. M.J. Burns The pharmacology and toxicology of atypical antipsychotic agents Clin Toxicol 39 2001 1 14
14. A.C. Springfield, E. Bodiford An overdose of risperidone J Anal Toxicol 20 1996 202 203
15. A.A. Acri, F.M. Henretig Effects of risperidone in overdose Am J Emerg Med 16 1998 498 501
16. Risperdal (package insert). Titusville, NJ: Janssen Pharmaceutica Products, L.P.; 2003.
17. J.T. Callaghan, R.F. Bergstrom, L.R. Ptak, C.M. Beasley Olanzapine Pharmacokinetic and pharmacodynamic profile Clin Pharmacokinet 37 1999 177 193
18. A.J. Jenkins, K.M. Sarconi, H.N. Raaf Determination of olanzapine in a postmortem case J Anal Toxicol 22 1998 605 609
19. J.E. Gerber, B. Cawthon Overdose and death with olanzapine: two case reports Am J Forensic Med Pathol 21 2000 249 251
20. U.S. Department of Health and Human Services Psychopharmacological Drugs Advisory Committee Meeting on NDA 21-253: Zyprexa. February 14, 2001 http://www.fda.gov/ohrms/dockets/ac/01/slides/3685s1.htm Accessed August 20, 2003
21. Zyprexa, Zyprexa Zydis (package insert). Indianapolis, IN: Eli Lilly and Company; 2004.
22. Eli Lilly and Company Zyprexa powder for solution for injection. Summary of product characteristics. 2001 http://www.lilly.co.uk/pdf/ zyprexa%20intramuscular.pdf Accessed September 1, 2003
23. C. Beedham, J.J. Miceli, R.S. Obach Ziprasidone metabolism, aldehyde oxidase, and clinical implications J Clin Psychopharmacol 23 2003 229 232
24. Geodon (package insert). New York, NY: Pfizer Inc.; 2002.
25. C. Prakash, A. Kamel, D. Cui, R.D. Whalen, J.J. Miceli, D. Tweedie Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions Br J Clin Pharmacol 49 Suppl 1 2000 35S 42S
26. J.J. Miceli, R.J. Anziano, L. Robarge, R.A. Hansen, A. Laurent The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers Br J Clin Pharmacol 49 Suppl 1 2000 65S 70S
27. J.J. Miceli, M. Smith, L. Robarge, T. Morse, A. Laurent The effects of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers Br J Clin Pharmacol 49 Suppl 1 2000 71S 76S
28. S. Burton, K. Heslop, K. Harrison, M. Barnes Ziprasidone overdose Am J Psychiatry 157 2000 835
29. M. House Overdose of ziprasidone Am J Psychiatry 159 2002 1061 1062
30. S.M. Bryant, J. Zilberstein, K.L. Cumpston, D.D. Magdziarz, D.D. Costerisan A case series of ziprasidone overdoses Vet Hum Toxicol 45 2003 81 82
31. ® capsules (Ziprasidone HCl). July 19, 2000 http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf Accessed August 25, 2003
32. S. Ahnve Correction of the QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction Am Heart J 109 1985 568 574
33. J. Morganroth, F.V. Brozowich, J.T McDonald Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia Am J Cardiol 76 1991 774 776
34. Royal College of Psychiatrists The association between antipsychotic drugs and sudden death: 1997 report of the Working Group of the Royal College of Psychiatrists Pharmacology Sub-Group. 1997 http://www.rcpsych.ac.uk/ publications/cr/council/cr57.pdf Accessed August 25, 2003
35. F. Dessertenne La tachycardie ventriculaire a deux foyers opposes variables Arch Mal Coeur Vaiss 59 1966 263 272
36. D.M. Krikler, P.V. Curry Torsade De Pointes, an atypical ventricular tachycardia Br Heart J 38 1976 117 120
37. C.S. Zee-Cheng, C.E. Mueller, C.F. Seifert, H.R. Gibbs Haloperidol and torsades de pointes Ann Intern Med 102 1985 418
38. S.A. Fayer Torsades de pointes ventricular tachyarrhythmia associated with haloperidol J Clin Psychopharmacol 6 1986 375 376
39. M. Kriwisky, G.Y. Perry, D. Tarchitsky, Y. Gutman, Y. Kishon Haloperidol-induced torsades de pointes Chest 98 1990 482 484
40. R.A. Henderson, S. Lane, J.A. Henry Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose Hum Exp Toxicol 10 1991 59 62
41. E. Metzger, R. Friedman Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill J Clin Psychopharmacol 13 1993 128 132
42. J.L. Wilt, A.M. Minnema, R.F. Johnson, A.M. Rosenblum Torsade de pointes associated with the use of intravenous haloperidol Ann Intern Med 119 1993 391 394
43. T.G. Di Salvo, P.T. O'Gara Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients Clin Cardiol 18 1995 285 290
44. D.O. Faigel, D.C. Metz, M.L. Kochman Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance Am J Gastroenterol 90 1995 822 824
45. N. Hunt, T.A. Stern The association between intravenous haloperidol and Torsades de Pointes Three cases and a literature review Psychosomatics 36 1995 541 549
46. J.M. O'Brien, R.P. Rockwood, K.I. Suh Haloperidol-induced torsade de pointes Ann Pharmacother 33 1999 1046 1050
47. N.D. Sharma, H.S. Rosman, I.D. Padhi, J.E. Tisdale Torsades de Pointes associated with intravenous haloperidol in critically ill patients Am J Cardiol 81 1998 238 240
48. L.P. Perrault, A.Y. Denault, M. Carrier, R. Cartier, S. Belisle Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery Can J Anaesth 47 2000 251 254
49. J.E. Tisdale, S. Rasty, I.D. Padhi, N.D. Sharma, H. Rosman The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes J Clin Pharmacol 41 2001 1310 1318
50. FDA Psychopharmacological Drugs Advisory Committee Briefing document for ziprasidone mesylate for intramuscular injection. February 15, 2001 http://www.fda.gov/ohrms/dockets/ac/01/briefing/3685b2_01_pfizer.pdf Accessed August 25, 2003
51. Miceli JJ, Anziano RJ, Swift RH, et al. IM ziprasidone and IM haloperidol show comparable change in QTc at Cmax. Poster presented at: 155th Annual Meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, Pa.
52. FDA Important drug warning. 2003 http://www.fda.gov/medwatch/SAFETY/2003/ risperdal.htm Accessed August 25, 2003
53. E. Wooltorton Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials CMAJ 167 2002 1269 1270
54. G.W. Currier, J.C.Y. Chou, D Feifel Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam Clin Psychiatry 65 2004 386 394
55. E. Richelson Receptor pharmacology of neuroleptics: relation to clinical effects J Clin Psychiatry 60 Suppl 10 1999 5 14
56. FDA Psychopharmacological Drugs Advisory Committee Briefing document for Zyprexa intramuscular (olanzapine for injection). January 11, 2001 http://www.fda.gov/ohrms/dockets/ac/01/briefing/3685b1_01_lilly.pdf Accessed August 20, 2003
57. K. Meehan, F. Zhang, S David A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania J Clin Psychopharmacol 21 2001 389 397
58. K.M. Meehan, H. Wang, S.R David Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia Neuropsychopharmacology 26 2002 494 504
59. J.E. Clinton, S. Sterner, Z. Stelmachers, E. Ruiz Haloperidol for sedation of disruptive emergency patients Ann Emerg Med 16 1987 319 322
60. C. Swett Jr, J.O. Cole, S.C. Hartz, S. Shapiro, D. Slone Hypotension due to chlorpromazine Relation to cigarette smoking, blood pressure, and dosage Arch Gen Psychiatry 34 1977 661 663
61. P.L. Man, C.H. Chen Rapid tranquilization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine Psychosomatics 14 1973 59 63
62. D.G. Daniel, S.G. Potkin, K.R. Reeves, R.H. Swift, E.P. Harrigan Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial Psychopharmacology (Berl) 155 2001 128 134
63. M.D. Lesem, J.M. Zajecka, R.H. Swift, K.R. Reeves, E.P. Harrigan Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients J Clin Psychiatry 62 2001 12 18
64. S. Brook, J.V. Lucey, K.P. Gunn Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis Ziprasidone I.M. Study Group J Clin Psychiatry 61 2000 933 941